What is ANVS (ANVS) stock price today?

ANVS (ANVS) is currently trading at $1.70, up 0.59% today.

What is ANVS P/E ratio?

ANVS's P/E ratio is -1.54. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ANVS return on equity (ROE)?

ANVS's return on equity (ROE) is -220.61%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is ANVS's market cap?

ANVS has a market capitalization of $33.45M.

NYSE · Biotechnology

ANVS (ANVS) Stock

$1.70 +0.59% NYSE: ANVS Healthcare

Valuation

Metric	Value
Price	$1.70
Market Cap	$33.45M
P/E Ratio	-1.54
P/B Ratio	2.89
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$5.50
52-Week Low	$1.54
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-220.61%
ROA	-1.06%
ROCE	-176.47%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	5.25

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-15.0M	$-26.0M	$-45.0M	$-27.0M	$-30.0M
Net Profit	$-14.0M	$-25.0M	$-56.0M	$-25.0M	$-29.0M
EPS	$-1.90	$-3.10	$-6.23	$-2009.77	$-1.40
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$46.0M	$36.0M	$10.0M	$14.0M	$21.0M
Total Liabilities	$2.0M	$8.0M	$18.0M	$5.0M	$4.0M
Cash	$46.0M	$28.0M	$6.0M	$11.0M	$20.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial NYSE · Jul 7, 2026 Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease MT Newswires · Jul 7, 2026 Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease GlobeNewswire · Jul 7, 2026 Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer GlobeNewswire · Jul 1, 2026 Annovis Bio Regains NYSE Listing Compliance GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-9.0M	$-17.0M	$-40.0M	$-21.9B	$-25.6B
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$26.7B	$34.6B
Net Cash Flow	$38.0M	$-17.0M	$-23.0M	$4.8B	$9.0B
Free Cash Flow	$-9.0M	$-17.0M	$-40.0M	$-21.9B	$-25.6B

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-75.13%
Quick Ratio	1.27
Interest Coverage	—
Return 1Y	-34.33%
Return 3Y	-87.26%
Return 5Y	-98.31%

Ownership

Insiders Held8.26%

Institutions Held16.70%

Institutions Float Held18.21%

Institutional Holder	Shares	Report Date
Marshall Wace LLP	1,187,499	2026-03-31
Vanguard Capital Management LLC	872,381	2026-03-31
Two Sigma Investments, LP	627,659	2026-03-31
Renaissance Technologies, LLC	347,600	2026-03-31
Geode Capital Management, LLC	247,513	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ATNM	$0.80	+1.32%	-1.07	$25.02M	0.00%
BCABBioAtla, Inc.	$3.40	+0.89%	-0.08	$4.29M	0.00%
BTAIBioXcel Therapeutics, Inc.	$0.87	+2.30%	-0.13	$26.77M	0.00%
CELUCelularity Inc.	$0.75	+0.13%	-0.20	$21.74M	0.00%
ELUT	$0.86	-5.33%	-1.24	$37.88M	0.00%

About ANVS

ANVS is led by CEO Maria L. Maccecchini, employs 8 people, headquartered in US, publicly traded since 2020.

ANVS stock trades at $1.70 with a market capitalization of $33.45M. The stock is valued at a price-to-earnings (P/E) ratio of -1.54, price-to-book of 2.89, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.54 and $5.50, and currently trades 69.1% below its 52-week high.

On profitability, ANVS generates a return on equity (ROE) of -220.61%, return on capital employed of -176.47%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks NYSE High ROE Stocks All stock screens

Run Stock Screener Investing Guides